source
- Gossamer ends $486M PAH partnership with Chiesi after phase 3 missGossamer Bio announced it is terminating its collaboration and licensing agreement with Italy's Chiesi, regaining worldwide development and commercial rights to its pulmonary arterial hypertension…
- AstraZeneca says it remains confident in its ADC pipeline after dropping two underperforming candidatesAstraZeneca executives told Fierce they are very confident in their internally developed antibody‑drug conjugate (ADC) program despite recent setbacks. The company has discontinued two ADC candida…